770-900 monthly LA abortions via telehealth pills now in 5th Circuit

For clinicians, health systems, and digital health leaders, mifepristone is not an edge case—medication abortion now accounts for at least 3 in 5 U.S. abortions. A ruling that requires in-person dispensing would force a reconfiguration of reproductive telehealth workflows, patient monitoring, and care navigation in states with bans and shield laws.

At the center of the latest abortion access battle is mifepristone, the first component of a two-drug regimen that now accounts for at least three in five U.S. abortions. On September 9, 2026, a three-judge panel of the New Orleans-based 5th U.S. Circuit Court of Appeals heard arguments over whether prescribing rules should be tightened so that mifepristone cannot be prescribed via telehealth or dispensed anywhere other than a medical facility. Louisiana Attorney General Liz Murrill and plaintiff Rosalie Markezich, who says she was coerced into taking abortion pills, brought the challenge. It is one of three cases making their way through the courts as abortion opponents seek to stop providers in states where abortion is legal from sending drugs into states where it is not.

“

Louisiana Attorney General Liz Murrill and plaintiff Rosalie Markezich, who says she was coerced into taking abortion pills, brought the challenge.

The legal stakes are unusually high. The U.S. Supreme Court has already said current prescribing and dispensing rules will remain in effect while this case is resolved, so even if the appeals panel agrees with the challengers, policy will not change immediately. But the momentum in the lower courts is running against the current framework: two district courts and three other three-judge panels on the 5th Circuit—one in this case and two in an earlier proceeding—have already agreed that the FDA's mifepristone rules are too loose. Wednesday's panel is composed of two judges nominated by Democratic presidents and one nominated by a Republican, creating meaningful uncertainty about whether it will align with those earlier findings.

The FDA is also in play. The agency says it is reviewing the prescribing rules and could call for a change, which means the judicial fight could be superseded or reinforced by administrative action. For legal professionals, the case is a test of whether FDA drug approval and risk evaluation conditions can be re-litigated years after approval through state attorney general enforcement and private tort claims. The combination of a state official's challenge with an individual coercion claim broadens the theories available to abortion opponents and could influence standing doctrine, preemption analysis, and the scope of federal regulatory authority.

For healthcare providers and health IT platforms, mifepristone is not a marginal issue. At least 3 in 5 U.S. abortions are now obtained using the two-drug combination of mifepristone and misoprostol, a regimen that has become standard because it can be administered at home after an online or telehealth consultation. That reality is visible in Louisiana, where a survey conducted for the Society of Family Planning estimates that between 770 and 900 women obtained abortions each month in 2025 by using pills prescribed online or by doctors or nurse practitioners in other states. If the 5th Circuit tightens rules to require in-person dispensing, that care pathway would be severed, forcing patients to travel, seek clinic-based care, or forgo treatment.

For biotech and pharmaceutical stakeholders, the case raises a broader regulatory risk. Mifepristone has been approved in the U.S. for decades and is subject to a specific FDA risk management framework. Re-litigating its dispensing conditions sends a signal that even long-approved reproductive health products could face new distribution constraints based on state-law challenges rather than clinical data. This could affect investment decisions, supply chain planning, and the willingness of telehealth platforms to carry reproductive health medications.